Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis
The MIPD approach predicted that 35% and 26% of the patients would need an optimized and intensified dosage regimen, respectively, compared to the regimen typically used in clinical practice. This analysis demonstrated its utility as a tool for selecting personalized UTK dosing regimens in clinical practice in order to optimize the probability of achieving targeted clinical outcomes in patients with psoriasis.
Authors
- Matilde Merino‐Sanjuán (ORCID: https://orcid.org/0000-0003-4956-0247)
- Elena Gras‐Colomer (ORCID: https://orcid.org/0000-0003-2148-3163)
- Marina Saez-Bello
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Mónica Climente Martí (ORCID: https://orcid.org/0000-0002-4387-1987)
- Víctor Mangas‐Sanjuán (ORCID: https://orcid.org/0000-0002-3388-5023)
- Karine Rodríguez-Fernández (ORCID: https://orcid.org/0009-0008-2065-7188)
- Almudena Mateu‐Puchades (ORCID: https://orcid.org/0000-0003-0545-6261)
- Javier Zarzoso-Foj (ORCID: https://orcid.org/0009-0007-4799-9076)
Institutions
- Universitat de València (ES)
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
- Hospital de Manises (ES)
- Universitat Politècnica de València (ES)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-10-04
- DOI
- https://doi.org/10.3390/pharmaceutics16101295
- Citations
- 4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.96